The DOI matches its Crossref record; 94 of the 96 references it cites were found in a registry or an index; 93 of the 158 sources its claims cite were checked for support.
From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy
Open accessAbstract
Liver cirrhosis, a chronic disease distinguished by extensive scarring in the liver, results in liver dysfunction and fatal complications such as portal hypertension and liver cancer. Although early interventions can retard or reverse early injury, advanced stages often call for liver transplantation-a therapy undermined by donor shortage and logistical setbacks. Emerging cell therapies, particularly those based on mesenchymal stem cells (MSCs), offer a novel approach to addressing these clinical needs. MSCs, self-renewing multipotent stromal cells, can differentiate into many cell types, including hepatocyte-like cells. Immune regulation, regenerative signaling, and anti-scarring effects are three mechanisms that underlie their therapeutic promise. MSCs modulate immune cells, suppressing inflammation and promoting tissue healing. MSCs release several growth factors and cytokines, including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and matrix metalloproteinases (MMPs), which participate in tissue regeneration. Among these, HGF is bivalent, as it supports hepatocyte proliferation while also inhibiting fibrosis and apoptosis, thereby allowing the tissue to repair and protect itself. Recent advances identify extracellular vesicles from MSCs (MSC-EVs) as a cell-free alternative. The vesicles contain bioactive cargo, including microRNAs and proteins, that regulate immune function, inhibit cell death, and facilitate liver repair. Preclinical models of cirrhosis in animals have demonstrated MSC-EVs to enhance liver function, reduce scarring, and improve survival. This review integrates current knowledge of MSC-based therapies, their mechanisms, clinical potential, and challenges associated with their deployment. More than 50 clinical trials are registered or planned to evaluate MSC-based treatments for liver cirrhosis. Preclinical and clinical outcomes are encouraging; however, further work is needed to optimize delivery strategies, confirm safety, and facilitate the universal clinical use of this approach. Advances in MSC-guided regenerative medicine have the potential to revolutionize therapy for end-stage liver disease, offering hope where traditional treatments fail.
Overview
CoChat Summary
## TL;DR
This review argues that mesenchymal stem cells (MSCs) are a promising regenerative therapy for liver cirrhosis because they combine immunomodulatory, antifibrotic, and pro-regenerative effects, with encouraging preclinical and early clinical results. It also emphasizes that translation to routine care still depends on larger randomized trials, standardized protocols, and better delivery strategies.
## Key findings
- The review states that more than 50 clinical trials are registered or planned to evaluate MSC-based treatments for liver cirrhosis.
- In the cited meta-analysis, 14 clinical trials were reviewed, and MSC therapy plus standard supportive care was reported to significantly improve liver function in cirrhosis of various etiologies.
- In an RCT of hepatitis B-related ACLF, intravenous BM-MSCs were associated with significant MELD improvement, reduced mortality, lower TNF-α and IL-6, and a significantly higher 24-week survival rate; the intervention was reported as safe with no severe adverse events.
- In a study of autologous BM-MSCs for alcoholic cirrhosis, histology showed 25% and 37% reductions in collagen deposition after single and double infusions, respectively.
## Methods
- This is a narrative review synthesizing mechanistic, preclinical, and clinical literature on MSC-based therapies for liver cirrhosis.
- The paper draws on preclinical animal models (chemically induced, surgically induced, and genetically engineered) and clinical trials across multiple etiologies and MSC sources.
- It summarizes outcomes using reported trial endpoints such as MELD score, fibrosis/collagen deposition, liver enzymes, albumin, survival, and adverse events.
## Limitations
- The paper explicitly states that heterogeneity of trial designs, small numbers of studies, and short follow-up durations do not permit firm conclusions.
- It also notes the need for larger, multicenter Phase III studies and standardized protocols to validate long-term efficacy and dosing.
- Evident from the text: much of the clinical evidence cited is early-phase, heterogeneous, and source-/delivery-dependent, which makes cross-trial comparison difficult.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
60 Valid · 21 Not valid · 40 Not checked · 41 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additionally, MSCs release various wound-healing factors, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), transforming growth factor-beta 1 (TGF-β1), interleukin-8 (IL-8), and monocyte chemoattractant protein-1 (MCP-1). Through paracrine signaling, these factors induce cell survival, migration, and extracellular matrix (EC”
§ From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy > Introduction
What the sources say
- Partly supportedcites [19] Ehlen QT, Costello JP, Mirsky NA, Slavin BV, Parra M, Ptashnik A, et al. Treatment of bone defects and nonunion via novel delivery mechanisms, growth factors, and stem cells: A review. ACS Biomaterials Sci Eng. 2024;10(12):7314–36. sourceExperimental — accuracy not yet measured
The Stem Cells > Acute Administration section reports improved bone healing with MSC-seeded scaffolds, and the Growth Factors section discusses VEGF, PDGF, and TGF-β in bone repair. The passages do not say that MSCs release the listed factors—including HGF, IL-8, and MCP-1—or that those factors act through paracrine signaling to produce the specified effects. Page numbers were not available in our copy. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [20] Hsiao ST-F, Asgari A, Lokmic Z, Sinclair R, Dusting GJ, Lim SY, et al. Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev. 2012;21(12):2189–203. source
- Not checked — no full text of the sourcecites [21] Jiang Z, Liu G, Meng F, Wang W, Hao P, Xiang Y, et al. Paracrine effects of mesenchymal stem cells on the activation of keratocytes. Br J Ophthalmol. 2017;101(11):1583–90. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Liver transplantation remains the only curative option for end-stage liver disease, and refinements in surgical procedures, immunosuppressive therapy, and postoperative management have significantly enhanced patient survival and quality of life.”
§ From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy > Introduction
What the sources say
- Not checked yetcites [10] Kim D-S, Yoon Y-I, Kim BK, Choudhury A, Kulkarni A, Park JY, et al. Asian Pacific association for the study of the liver clinical practice guidelines on liver transplantation. Hep Intl. 2024;18(2):299–383. source
Checked before — its earlier verdict is held back until a new check runs.
- Supportedcites [11] Khalil A, Quaglia A, Gélat P, Saffari N, Rashidi H, Davidson B. New developments and challenges in liver transplantation. J Clin Med. 2023;12(17):5586. source
The paper’s Abstract describes liver transplantation as the only definitive treatment for patients diagnosed with late-stage liver disease and identifies it as an established treatment for end-stage liver disease. The Conclusions also describe it as an effective treatment for acute and chronic liver failure. This supports the cited claim’s use of “only curative option.” (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not checked yet
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cirrhosis, if in early stages, can be reversible if the etiologic factor (e.g., viral hepatitis or alcohol use) is addressed early through interventions such as antiviral therapy or extended alcohol abstinence.”
§ From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy > Introduction
What the sources say
- Not checked — no full text of the sourcecites [7] Sohrabpour AA, Mohamadnejad M, Malekzadeh R. The reversibility of cirrhosis. Aliment Pharmacol Ther. 2012;36(9):824–32. source
- Partly supportedcites [8] Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4):875. sourceExperimental — accuracy not yet measured
Section 4, “Resolution of Liver Fibrosis” (page not provided), reports that removing the cause of chronic HBV or HCV infection can reverse fibrosis, including advanced fibrosis, though reversal is not universal. Section 3.3 identifies alcohol as a cause of fibrosis, but the paper does not specifically say that extended alcohol abstinence reverses cirrhosis or establish the claim’s early-intervention condition. (LLM, conf=0.87)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“MSCs release several growth factors and cytokines, including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and matrix metalloproteinases (MMPs), which participate in tissue regeneration.”
§ From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy > Abstract Liver cirrhosis, a chronic disease distinguished by extensive scarring in the liver, results in liver dysfunction and fatal complications such as portal hypertension and liver cancer. Although early interventions can retard or reverse early injury, advanced stages often call for liver transplantation—a therapy undermined by donor shortage and logistical setbacks. Emerging cell therapies, particularly those based on mesenchymal stem cells (MSCs), offer a novel approach to addressing these clinical needs. MSCs, self-renewing multipotent stromal cells, can differentiate into many cell types, including hepatocyte-like cells. Immune regulation, regenerative signaling, and anti-scarring effects are three mechanisms that underlie their therapeutic promise. MSCs modulate immune cells, suppressing inflammation and promoting tissue healing. MSCs release several growth factors and cytokines, including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and matrix metalloproteinases (MMPs), which participate in tissue regeneration. Among these, HGF is bivalent, as it supports hepatocyte proliferation while also inhibiting fibrosis and apoptosis, thereby allowing the tissue to repair and protect itself. Recent advances identify extracellular vesicles from MSCs (MSC-EVs) as a cell-free alternative. The vesicles contain bioactive cargo, including microRNAs and proteins, that regulate immune function, inhibit cell death, and facilitate liver repair. Preclinical models of cirrhosis in animals have demonstrated MSC-EVs to enhance liver function, reduce scarring, and improve survival. This review integrates current knowledge of MSC-based therapies, their mechanisms, clinical potential, and challenges associated with their deployment. More than 50 clinical trials are registered or planned to evaluate MSC-based treatments for liver cirrhosis. Preclinical and clinical outcomes are encouraging; however, further work is needed to optimize delivery strategies, confirm safety, and facilitate the universal clinical use of this approach. Advances in MSC-guided regenerative medicine have the potential to revolutionize therapy for end-stage liver disease, offering hope where traditional treatments fail.
What the sources say
- Partly supportedcites [19] Ehlen QT, Costello JP, Mirsky NA, Slavin BV, Parra M, Ptashnik A, et al. Treatment of bone defects and nonunion via novel delivery mechanisms, growth factors, and stem cells: A review. ACS Biomaterials Sci Eng. 2024;10(12):7314–36. sourceExperimental — accuracy not yet measured
The Growth Factors section says VEGF contributes to bone remodeling and regeneration, and Stem Cells > Acute Administration describes faster bone healing with MSC-seeded scaffolds (page numbers unavailable). Neither passage says MSCs release VEGF, HGF, EGF, or MMPs; the claimed secretion of those substances is unsupported by our copy. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [20] Hsiao ST-F, Asgari A, Lokmic Z, Sinclair R, Dusting GJ, Lim SY, et al. Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue. Stem Cells Dev. 2012;21(12):2189–203. source
- Not checked — no full text of the sourcecites [21] Jiang Z, Liu G, Meng F, Wang W, Hao P, Xiang Y, et al. Paracrine effects of mesenchymal stem cells on the activation of keratocytes. Br J Ophthalmol. 2017;101(11):1583–90. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Reversion of fibrosis, however, is a gradual process that typically takes years to achieve [7, 8].”
§ From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy > Introduction
What the sources say
- Not checked — no full text of the sourcecites [7] Sohrabpour AA, Mohamadnejad M, Malekzadeh R. The reversibility of cirrhosis. Aliment Pharmacol Ther. 2012;36(9):824–32. source
- Partly supportedcites [8] Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020;9(4):875. sourceExperimental — accuracy not yet measured
Section 4, “Resolution of Liver Fibrosis” (page unavailable), says spontaneous resolution after removal or treatment of the inflammatory trigger occurs slowly. It does not say that reversion typically takes years, so the claimed timeframe is unsupported. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
58 more claims · 23 with their cited sources checked
Create a free account to see all 162 claims and to verify the 11 references still open.
- It may state two separate claims as one. 89
- Probably not a substantial claim. 18
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
Cited work W109771801 · retraction date not known · this paper published 2025-08-05
Citations
Cites
1 retracted
(2013) · Europe PMC (PubMed Central) · Cited by 75
RetractedExtracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783 · cited 5×
“…functionalized with ligands for liver targeting (e.g., galactose)—aspects that have been superficially addressed in previous clinical reviews; [2] integration of next-generation tools such as CRISPR-edited CAR-T cells against PDGFR-β + hepatic stellate cells and digital twin simulations to…”
InfluentialLee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898
The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases
Cabral-Pacheco, G. A., Garza-Veloz, I., Castruita-De la Rosa, C., Ramirez-Acuña, J. M., Perez-Romero, B. A., Guerrero-Rodriguez, J. F., Martinez-Avila, N., & Martinez-Fierro, M. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249739 · Cited by 1,820 · cited 1×
“Specifically, miR-223 suppresses pro-inflammatory signaling pathways [61], while miR-181 selectively inhibits collagen-producing genes, thereby disassembling the molecular scaffolding of fibrosis [62, 63].”
Ginès, P., Krag, A., Abraldes, J. G., Solà, E., Fabrellas, N., & Kamath, P. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01374-x · Cited by 1,663
Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications
Wang, Y., Chen, X., Cao, W., & Shi, Y. (2014) · Nature Immunology · doi:10.1038/ni.3002 · Cited by 1,452 · cited 1×
“…growth factor β; PDGF: Platelet-Derived Growth Factor; ERK: extracellular-signal-regulated kinase; MAPK: mitogen-activated protein kinase; TIMPs: tissue inhibitors of metalloproteinases; MMPs: matrix metalloproteinase; HSC: Hepatic Stellate Cell suitable for both autologous and allogeneic use [41].”
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237 · cited 1×
“Reversion of fibrosis, however, is a gradual process that typically takes years to achieve [7, 8].”
Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases
Shi, Y., Wang, Y., Li, Q., Liu, K., Hou, J., Shao, C., & Wang, Y. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0023-5 · Cited by 1,223 · cited 1×
“However, current evidence suggests that their significant therapeutic actions are paracrine-mediated rather than via direct differentiation [42, 43].”
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074 · cited 1×
“Their potent immunomodulatory properties, rapid proliferation, and ‘off-the-shelf’ availability enable faster improvements in decompensated cirrhosis and acute liver failure [79].”
Cited by
Choi, S., & Jeong, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020619 · Cited by 12
“The multifunctionality of MSCs provides a biological rationale for testing MSC-based strategies for the treatment of liver diseases, such as acute injury, acute-on-chronic liver failure, and cirrhosis [10–12].”
Mesenchymal stem cell therapy for end-stage liver disease: adversity and opportunity
Li, S., Wang, Y., Li, S., Zhu, Y., Du, Y., Zheng, X., & Wu, J. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04788-3 · Cited by 6
Nie, R., Duan, Y., Cao, X., Pang, M., Wang, Z., & Fan, H. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156382 · Cited by 4
Huang, Y., Cheng, R., Wang, G., Xu, Z., Liu, S., Wan, Y., Hou, X., & Wang, J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1677021 · Cited by 5
The role of thrombospondin-1 in dermatological conditions
Chen, L.-S., Zheng, B., Zhao, C.-Y., He, C., & Xing-hua, G. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1724955 · Cited by 4
“Beyond THBS1, additional pathways—including those mediated by MMPs and ROS—can also activate TGF-β and exacerbate fibrosis (92).”
Metadata
- Authors
- Bozorgi, V., Babaahmadi, M., Salehi, M., Vafaeimanesh, J., & Hajizadeh-Saffar, E.
- Affiliations
- Qom University of Medical Science and Health Services (IR)
- Royan Institute (IR)
- Corresponding author
- Vafaeimanesh, Jamshid
- Venue
- Stem Cell Research & Therapy
- Published
- 2025-08-05
- Volume
- 16
- Issue
- 1
- Pages
- 421-421
- ISSN
- 1757-6512 (ISSN-L)
- PMC
- PMC12326728
- OpenAlex
- W4412991144
- Cited by
- 11
- References
- 96
- Citations by year
- 2026: 9 · 2025: 2
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Stem Cell Research & Therapy (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- mesenchymal stem cells, liver cirrhosis, liver fibrosis, hepatocyte growth factor, extracellular vesicles, cell-free therapy, regenerative medicine, cell therapy, immune regulation, tissue regeneration, microRNA, clinical trials, end-stage liver disease, hepatocyte-like cells
- MeSH terms
- Animals, Clinical Trials as Topic, Humans, Liver Cirrhosis, Liver Regeneration, Signal Transduction, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy. https://app.cochat.ai/papers/10.1186/s13287-025-04535-8
- The paper
- Bozorgi, V., Babaahmadi, M., Salehi, M., Vafaeimanesh, J., & Hajizadeh-Saffar, E. (2025). From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-025-04535-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.